HAART

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

Single DermaVir Immunization in HIV-1 Infected Patients on HAART

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

ARVs to Prevent Breastmilk HIV:Viral and Immune Responses

Valproic Acid and Its Effects on HIV Latent Reservoirs

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda

Antiretroviral Therapy for Acute and Chronic HIV Infection

Intermittent Versus Continuous Medication in the Treatment of HIV

Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients

HIV - Monotherapy in Switzerland (MOST-ch)

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)

Children With HIV and Asthma (CHIVAS)